-The Telegraph New Delhi: The sale of drug combinations containing last-resort antibiotics is rising faster than overall antibiotics sales in India, health researchers have said in a study that also highlights the government's failure to stop the sale of irrational and unapproved antibiotic cocktails. While total antibiotics sales in India rose 26 per cent over a four-year period, says the study, there was a 174 per cent increase in the sales of...

-Livemint.com Govt plans to?help firms revamp manufacturing units,?refurbish machinery,?ensure subsidized power in bid to produce drugs such as penicillin at competitive rates New Delhi: The Department of Pharmaceuticals (DoP), during a meeting on Wednesday, urged pharma companies to strive for self-sufficiency in critical drugs like penicillin, rifampicin and insulin, in a sign of government concern over India’s dependence on Chinese imports. A large number of so-called active pharmaceutical ingredients (APIs), or bulk drugs,...

-The Times of India NEW DELHI: In a move to ensure efficacy of medicines sold in India, the drug regulator has made it mandatory for companies to include Indian patients in global clinical trials if they want to market in India a new drug developed outside the country. The decision was taken in a recent technical committee meeting, headed by director general of health services Jagdish Prasad. The committee, which was formed...

-Livemint.com India’s new industrial policy is an opportunity to address the problems of low R&D spending and tough competition from cheap Chinese imports The framing of the new industrial policy should be seen as an opportunity to chart a meaningful path for industry’s role in India’s development. The recently released discussion paper by the department of industrial policy and promotion mentions two points that need to be examined closely to grasp the...

-The Times of India In a first for a medical device, the public interest provision in the Drug Price Control Order (DPCO) 2013 was used by the National Pharmaceutical Pricing Authority to cap the price of knee implants. The NPPA cited "exorbitant prices being charged from patients in a non-regulated market" and "a failed market system where asymmetry of information between patient and the doctor has resulted into unethical practices and...